Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

This phase I trial tests the safety, side effects and best dose of futibatinib with paclitaxel and ramucirumab for the treatment of patients with gastric, gastroesophageal junction or esophageal adenocarcinoma that has spread to nearby tissue or lymph nodes (locally advanced) or that cannot be removed by surgery (unresectable). Futibatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Ramucirumab is a monoclonal a

Trial Details

NCT ID
NCT07594548
Phase
PHASE1
Sponsor
Northwestern University
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Biospecimen Collection
  • Computed Tomography
  • Futibatinib
  • Magnetic Resonance Imaging
  • Paclitaxel
  • Ramucirumab
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

  • Patients must have histologically or cytologically confirmed locally advanced/unresectable gastric, gastroesophageal junction, or esophageal adenoc…
  • Note: Histological or cytological test reports from external laboratories outside of Northwestern University (NU) will also be accepted
  • Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
  • Note: Patients must have documented unresectable and/or metastatic disease on CT or MRI imaging completed prior to registration. Imaging must have …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →